An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer

an attempt to identify clinical and biological factors determining prognosis

A. Di Leo, E. Bajetta, L. Biganzoli, S. Bohm, L. Mariani, S. Mènard, S. Pilotti, M. Fabbiani, V. Gebbia, S. Oriana, F. Ottone, G. Riboldi, C. Sava, G. Spatti, F. Zunino, F. Di Re

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The aim of the present study was to determine the activity of a combined regimen of mitoxantrone (DHAD) and ifosfamide (IFO) and identify clinical and biological factors with prognostic importance for the second-line treatment of ovarian cancer. The following factors were investigated for their prognostic importance: age, disease sites, platinum responsiveness, histological grade, the presence of clinically/radiologically detectable versus not detectable disease, residual disease volume after first surgery, p53 protein, c-erbB-2 oncoprotein and laminin receptor. 72 patients entered the trial. DHAD and IFO therapy led to a 15% response rate among the 47 cases with clinically/radiologically detectable disease (1 complete and 6 partial responses), with a median response duration of 4 months. The response rate was significantly different according to platinum responsiveness (4% objective responses in platinum-resistant versus 27% in platinum-sensitive disease). The time to treatment failure (TTF) and overall survival (OS) were affected by the presence of clinically detectable disease at study entry (median TTF 4 months in the presence of clinically/radiologically detectable disease versus 9 months if the disease was not similarly detectable, P = 0.02; median OS 10 months versus 21 months, P = 0.01). Initially overexpressed in only a few tumours, the c-erbB-2 oncoprotein became overexpressed in 36% of platinum-resistant tumours; this modulation did not occur in platinum-sensitive tumours. Furthermore, laminin receptor was expressed in 77% of platinum-sensitive versus 39% of platinum-resistant patients. There were no differences in p53 protein expression according to drug responsiveness.

Original languageEnglish
Pages (from-to)2248-2254
Number of pages7
JournalEuropean Journal of Cancer
Volume31
Issue number13-14
DOIs
Publication statusPublished - 1995

Fingerprint

Biological Factors
Platinum
Laminin Receptors
Ifosfamide
Oncogene Proteins
Therapeutics
Treatment Failure
ErbB-2 Receptor
Neoplasms
Mitoxantrone
Residual Volume
Survival
Ovarian epithelial cancer
Ovarian Neoplasms
Proteins
Pharmaceutical Preparations

Keywords

  • ovarian cancer
  • prognostic factors
  • second-line treatment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology

Cite this

An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer : an attempt to identify clinical and biological factors determining prognosis. / Di Leo, A.; Bajetta, E.; Biganzoli, L.; Bohm, S.; Mariani, L.; Mènard, S.; Pilotti, S.; Fabbiani, M.; Gebbia, V.; Oriana, S.; Ottone, F.; Riboldi, G.; Sava, C.; Spatti, G.; Zunino, F.; Di Re, F.

In: European Journal of Cancer, Vol. 31, No. 13-14, 1995, p. 2248-2254.

Research output: Contribution to journalArticle

Di Leo, A, Bajetta, E, Biganzoli, L, Bohm, S, Mariani, L, Mènard, S, Pilotti, S, Fabbiani, M, Gebbia, V, Oriana, S, Ottone, F, Riboldi, G, Sava, C, Spatti, G, Zunino, F & Di Re, F 1995, 'An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis', European Journal of Cancer, vol. 31, no. 13-14, pp. 2248-2254. https://doi.org/10.1016/0959-8049(95)00481-5
Di Leo, A. ; Bajetta, E. ; Biganzoli, L. ; Bohm, S. ; Mariani, L. ; Mènard, S. ; Pilotti, S. ; Fabbiani, M. ; Gebbia, V. ; Oriana, S. ; Ottone, F. ; Riboldi, G. ; Sava, C. ; Spatti, G. ; Zunino, F. ; Di Re, F. / An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer : an attempt to identify clinical and biological factors determining prognosis. In: European Journal of Cancer. 1995 ; Vol. 31, No. 13-14. pp. 2248-2254.
@article{96cbc5ccf1304d42bb233bf4af7fe90e,
title = "An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis",
abstract = "The aim of the present study was to determine the activity of a combined regimen of mitoxantrone (DHAD) and ifosfamide (IFO) and identify clinical and biological factors with prognostic importance for the second-line treatment of ovarian cancer. The following factors were investigated for their prognostic importance: age, disease sites, platinum responsiveness, histological grade, the presence of clinically/radiologically detectable versus not detectable disease, residual disease volume after first surgery, p53 protein, c-erbB-2 oncoprotein and laminin receptor. 72 patients entered the trial. DHAD and IFO therapy led to a 15{\%} response rate among the 47 cases with clinically/radiologically detectable disease (1 complete and 6 partial responses), with a median response duration of 4 months. The response rate was significantly different according to platinum responsiveness (4{\%} objective responses in platinum-resistant versus 27{\%} in platinum-sensitive disease). The time to treatment failure (TTF) and overall survival (OS) were affected by the presence of clinically detectable disease at study entry (median TTF 4 months in the presence of clinically/radiologically detectable disease versus 9 months if the disease was not similarly detectable, P = 0.02; median OS 10 months versus 21 months, P = 0.01). Initially overexpressed in only a few tumours, the c-erbB-2 oncoprotein became overexpressed in 36{\%} of platinum-resistant tumours; this modulation did not occur in platinum-sensitive tumours. Furthermore, laminin receptor was expressed in 77{\%} of platinum-sensitive versus 39{\%} of platinum-resistant patients. There were no differences in p53 protein expression according to drug responsiveness.",
keywords = "ovarian cancer, prognostic factors, second-line treatment",
author = "{Di Leo}, A. and E. Bajetta and L. Biganzoli and S. Bohm and L. Mariani and S. M{\`e}nard and S. Pilotti and M. Fabbiani and V. Gebbia and S. Oriana and F. Ottone and G. Riboldi and C. Sava and G. Spatti and F. Zunino and {Di Re}, F.",
year = "1995",
doi = "10.1016/0959-8049(95)00481-5",
language = "English",
volume = "31",
pages = "2248--2254",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "13-14",

}

TY - JOUR

T1 - An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer

T2 - an attempt to identify clinical and biological factors determining prognosis

AU - Di Leo, A.

AU - Bajetta, E.

AU - Biganzoli, L.

AU - Bohm, S.

AU - Mariani, L.

AU - Mènard, S.

AU - Pilotti, S.

AU - Fabbiani, M.

AU - Gebbia, V.

AU - Oriana, S.

AU - Ottone, F.

AU - Riboldi, G.

AU - Sava, C.

AU - Spatti, G.

AU - Zunino, F.

AU - Di Re, F.

PY - 1995

Y1 - 1995

N2 - The aim of the present study was to determine the activity of a combined regimen of mitoxantrone (DHAD) and ifosfamide (IFO) and identify clinical and biological factors with prognostic importance for the second-line treatment of ovarian cancer. The following factors were investigated for their prognostic importance: age, disease sites, platinum responsiveness, histological grade, the presence of clinically/radiologically detectable versus not detectable disease, residual disease volume after first surgery, p53 protein, c-erbB-2 oncoprotein and laminin receptor. 72 patients entered the trial. DHAD and IFO therapy led to a 15% response rate among the 47 cases with clinically/radiologically detectable disease (1 complete and 6 partial responses), with a median response duration of 4 months. The response rate was significantly different according to platinum responsiveness (4% objective responses in platinum-resistant versus 27% in platinum-sensitive disease). The time to treatment failure (TTF) and overall survival (OS) were affected by the presence of clinically detectable disease at study entry (median TTF 4 months in the presence of clinically/radiologically detectable disease versus 9 months if the disease was not similarly detectable, P = 0.02; median OS 10 months versus 21 months, P = 0.01). Initially overexpressed in only a few tumours, the c-erbB-2 oncoprotein became overexpressed in 36% of platinum-resistant tumours; this modulation did not occur in platinum-sensitive tumours. Furthermore, laminin receptor was expressed in 77% of platinum-sensitive versus 39% of platinum-resistant patients. There were no differences in p53 protein expression according to drug responsiveness.

AB - The aim of the present study was to determine the activity of a combined regimen of mitoxantrone (DHAD) and ifosfamide (IFO) and identify clinical and biological factors with prognostic importance for the second-line treatment of ovarian cancer. The following factors were investigated for their prognostic importance: age, disease sites, platinum responsiveness, histological grade, the presence of clinically/radiologically detectable versus not detectable disease, residual disease volume after first surgery, p53 protein, c-erbB-2 oncoprotein and laminin receptor. 72 patients entered the trial. DHAD and IFO therapy led to a 15% response rate among the 47 cases with clinically/radiologically detectable disease (1 complete and 6 partial responses), with a median response duration of 4 months. The response rate was significantly different according to platinum responsiveness (4% objective responses in platinum-resistant versus 27% in platinum-sensitive disease). The time to treatment failure (TTF) and overall survival (OS) were affected by the presence of clinically detectable disease at study entry (median TTF 4 months in the presence of clinically/radiologically detectable disease versus 9 months if the disease was not similarly detectable, P = 0.02; median OS 10 months versus 21 months, P = 0.01). Initially overexpressed in only a few tumours, the c-erbB-2 oncoprotein became overexpressed in 36% of platinum-resistant tumours; this modulation did not occur in platinum-sensitive tumours. Furthermore, laminin receptor was expressed in 77% of platinum-sensitive versus 39% of platinum-resistant patients. There were no differences in p53 protein expression according to drug responsiveness.

KW - ovarian cancer

KW - prognostic factors

KW - second-line treatment

UR - http://www.scopus.com/inward/record.url?scp=0029592638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029592638&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(95)00481-5

DO - 10.1016/0959-8049(95)00481-5

M3 - Article

VL - 31

SP - 2248

EP - 2254

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 13-14

ER -